Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.

abstract：PURPOSE:The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly irinotecan as salvage treatment for patients with platinum- and taxanes-resistant advanced epithelial ovarian cancer. METHODS:Fifty-two patients with platinum- and taxanes-resistant advanced epithelia...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu Y,Ren Z,Xu S,Bai H,Ma N,Wang F

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:Troxacitabine (BCH-4556, l-(-)-OddC, Troxatyl) is a novel beta- l-nucleoside analogue with potent antineoplastic activity both in vitro and in several tumor models in vivo, and is presently in phase II clinical trials. The combination of the cytosine analogues troxacitabine and araC (1-beta- d-arabinofuranosylc...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffard DY,Jolivet J,Leblond L,Hamelin B,Ouellet F,Barbeau S,Richard A,Gourdeau H

更新日期：2003-12-01 00:00:00

abstract：:A novel antitumor compound, N-beta-dimethyl-aminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]-phenazine-6-carboxamide sodium salt (NC-190) was evaluated for its antitumor activity in experimental murine tumor systems. In the initial studies with P388 leukemia (i.p.-i.p.), NC-190 led to an increase of greater than 200%...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakaike S,Yamagishi T,Samata K,Nishida K,Inazuki K,Ichihara T,Migita Y,Otomo S,Aihara H,Tsukagoshi S

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Afatinib is an irreversible ErbB family blocker currently under evaluation in late-stage clinical trials. This study primarily assessed the cardiac safety, pharmacokinetics and antitumor activity of afatinib in cancer patients. METHODS:In this multicenter, Phase II, open-label, single-arm trial, 60 patients wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Molife LR,Rudman SM,Alam S,Tan DS,Kristeleit H,Middleton G,Propper D,Bent L,Stopfer P,Uttenreuther-Fischer M,Wallenstein G,de Bono J,Spicer J

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Abiraterone became a standard hormonal therapy for patients with metastatic castration-resistance prostate cancer (mCRPC). However, patients may experience primary resistance to treatment. To date, few predictive biomarkers of efficacy have been identified. Our aim was to investigate the association between ...

journal_title：Cancer chemotherapy and pharmacology

authors： Crucitta S,Del Re M,Paolieri F,Bloise F,Sbrana A,Sammarco E,Mercinelli C,Cucchiara F,Fontanelli L,Galli L,Danesi R

更新日期：2020-10-01 00:00:00

abstract：:Recent advances in cDNA microarray techniques have enabled us to study the expression of many genes simultaneously. As gastric cancer remains one of the most common cancers in Japan, we studied gene expression profiles in gastric cancer by cDNA microarray analysis to determine if it would be clinically useful. We demo...

journal_title：Cancer chemotherapy and pharmacology

authors： Haraguchi N,Inoue H,Mimori K,Tanaka F,Utsunomiya T,Yoshikawa K,Mori M

更新日期：2004-09-01 00:00:00

abstract：PURPOSE:Standardized enumeration of CEC counts is required to minimize variability and allow cross-studies comparisons. The purpose of this paper is to identify CEC threshold proposal, by CellSearch system, for determining response to bevacizumab-based chemotherapy in metastatic colorectal cancer. METHODS:From July 20...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsusaka S,Suenaga M,Mishima Y,Takagi K,Terui Y,Mizunuma N,Hatake K

更新日期：2011-09-01 00:00:00

abstract：PURPOSE:MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor vascular endothelial cells. This study determined the safety, pharmacokinetics, and acute anti-vascular effects of MN-029. METHODS:Patients were treate...

journal_title：Cancer chemotherapy and pharmacology

authors： Ricart AD,Ashton EA,Cooney MM,Sarantopoulos J,Brell JM,Feldman MA,Ruby KE,Matsuda K,Munsey MS,Medina G,Zambito A,Tolcher AW,Remick SC

更新日期：2011-10-01 00:00:00

abstract：:The local therapeutic effects and 5-year survival rates obtained following subsegmental transcatheter arterial embolization (TAE) therapy for small hepatocellular carcinomas (HCCs) were retrospectively analyzed. A total of 124 nodular-type HCC lesions measuring less than 4 cm in diameter in 100 patients with liver cir...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsui O,Kadoya M,Yoshikawa J,Gabata T,Takashima T,Demachi H

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Little information is available about changes in renal function after cisplatin-based chemotherapy (CBCT) in patients with a solitary kidney. The authors evaluated the renal safety and efficacy of CBCT after nephroureterectomy for upper urinary tract-urothelial carcinoma (UUT-UC). METHODS:The data of patients ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cho KS,Joung JY,Seo HK,Cho IC,Chung HS,Chung J,Lee KH

更新日期：2011-04-01 00:00:00

abstract：:The purpose of this study was to determine long-term renal platinum excretion after chemotherapy with cisplatin. We examined urinary platinum concentrations in 23 men at 150-3022 days after anticancer treatment for testicular neoplasm. Spot urine samples were analyzed by voltammetry. This new, subtle method with a det...

journal_title：Cancer chemotherapy and pharmacology

authors： Schierl R,Rohrer B,Hohnloser J

更新日期：1995-01-01 00:00:00

abstract：:The cytotoxic effects of ketoconazole, an antifungal agent known to have some activity against human prostate cancer, adrenal cancer, and male metastatic breast cancer, were evaluated using colony-growth and clonogenic assays in eight malignant cell lines. The cytotoxicity of ketoconazole showed a dose- and time-depen...

journal_title：Cancer chemotherapy and pharmacology

authors： Rochlitz CF,Damon LE,Russi MB,Geddes A,Cadman EC

更新日期：1988-01-01 00:00:00

abstract：BACKGROUND:The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA-mutated cancer. This Phase I, open-label, three-part study (Parts A-C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of olaparib when administered in tablet formulation. METHODS:PK d...

journal_title：Cancer chemotherapy and pharmacology

authors： Plummer R,Swaisland H,Leunen K,van Herpen CM,Jerusalem G,De Grève J,Lolkema MP,Soetekouw P,Mau-Sørensen M,Nielsen D,Spicer J,Fielding A,So K,Bannister W,Molife LR

更新日期：2015-10-01 00:00:00

abstract：:P388 murine leukemic cells lines which were resistant (P388R) or sensitive (P388S) to adriamycin (adr) were used to evaluate the potential utility of in vitro clonogenic assays for detecting and quantitating the number of adr-resistant cells present in a cell mixture. The progeny of P388S cells that had been exposed f...

journal_title：Cancer chemotherapy and pharmacology

authors： Dong GW,Preisler HD,Priore R

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:To evaluate whether celecoxib alters the conversion of gemcitabine into its active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), in peripheral blood mononuclear cells (PBMCs). METHODS:Patients with advanced pancreatic cancer who had not received chemotherapy and had acceptable organ function were el...

journal_title：Cancer chemotherapy and pharmacology

authors： Xiong HQ,Plunkett W,Wolff R,Du M,Lenzi R,Abbruzzese JL

更新日期：2005-06-01 00:00:00

abstract：:To test the feasibility of a regimen of high-dose cisplatin, ifosfamide, and etoposide (VP-16; VIPP regimen), we registered 15 patients with advanced non-small-cell lung cancer in a phase I trial of the Northern California Oncology Group. One cycle of treatment consisted of high-dose cisplatin given at 100 mg/m2 i.v. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Perez EA,Sowray PC,Gardner SL,Gandara DR

更新日期：1994-01-01 00:00:00

abstract：:A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna. Preoperative doxorubicin was given intra-arterially for lesions of the lower extremities. Of 47 evaluab...

journal_title：Cancer chemotherapy and pharmacology

authors： Azzarelli A,Quagliuolo V,Casali P,Fissi S,Montalto F,Santoro A

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:We have developed and evaluated a CNS-targeted chemotherapy regimen based on the pharmacokinetic properties of the individual drugs in the combination. PATIENTS AND METHODS:In a twin-track study, 16 patients with secondary CNS lymphoma (SCNSL) and 8 with primary CNS lymphoma (PCNSL) were treated with IDARAM wh...

journal_title：Cancer chemotherapy and pharmacology

authors： Moreton P,Morgan GJ,Gilson D,Smith GM,McVerry BA,Davies JM,Mackie MJ,Bolam S,Jalihal SS,Howard MR,Parapia LA,Williams AT,Child JA,Central and Southern Lymphoma Group.

更新日期：2004-04-01 00:00:00

abstract：PURPOSE:The established treatment for small-cell lung cancer has been a cisplatin-etoposide combination, as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide but this has been unacceptable due to the toxicity. This toxicity could be attributed to the thre...

journal_title：Cancer chemotherapy and pharmacology

authors： Stathopoulos GP,Trafalis D,Dimitroulis J,Kosmas Ch,Stathopoulos J,Tsavdaridis D

更新日期：2013-02-01 00:00:00

abstract：:Hexadecylphosphocholine (HPC) and octadecylphosphocholine (OPC) show very potent antitumor activity against autochthonous methylnitrosourea-induced mammary carcinomas in rats. The longer-chain and unsaturated homologue erucylphosphocholine (EPC) forms lamellar structures rather than micelles, but nonetheless exhibits ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kötting J,Berger MR,Unger C,Eibl H

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. METHODS:We evaluated ...

journal_title：Cancer chemotherapy and pharmacology

authors： Martell RE,Peterson BL,Cohen HJ,Petros WP,Rai KR,Morrison VA,Elias L,Shepherd L,Hines J,Larson RA,Schiffer CA,Hurwitz HI

更新日期：2002-07-01 00:00:00

abstract：PURPOSE:While the target of many anticancer agents has been identified, the processes leading to killing of the cancer cells and the molecular basis of resistance to the drugs are not well understood. We used human gastrointestinal cancer cell lines and examined how anticancer agents induced cell killing and how the ch...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto M,Maehara Y,Oda S,Ichiyoshi Y,Kusumoto T,Sugimachi K

更新日期：1999-01-01 00:00:00

abstract：:A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

journal_title：Cancer chemotherapy and pharmacology

authors： Looby M,Linke R,Weiss M

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:This study was designed to evaluate the anti-tumor activity and toxicity profile of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma (NPC) who had been pretreated with platinum-based chemotherapy. METHOD:This is an open label, single arm phase II trial. All patients were treated ...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang L,Zhang Y,Huang PY,Xu F,Peng PJ,Guan ZZ

更新日期：2008-01-01 00:00:00

abstract：PURPOSE:To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours. METHODS:Tumours were induced in female Wistar rats by in...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu JJ,Ching LM,Goldthorpe M,Sutherland R,Baguley BC,Kirker JA,McKeage MJ

更新日期：2007-04-01 00:00:00

abstract：PURPOSE:6-Gingerol, a major biochemical and pharmacological active ingredient of ginger, has shown anti-inflammatory and antitumor activities against various cancers. Searching for natural products with fewer side effects for developing adjunctive therapeutic options is necessary. METHODS:The effects of 6-gingerol on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu S,Zhang H,Liu T,Yang W,Lv W,He D,Guo P,Li L

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines. METHODS:The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were comple...

journal_title：Cancer chemotherapy and pharmacology

authors： Navo MA,Smith JA,Gaikwad A,Burke T,Brown J,Ramondetta LM

更新日期：2008-08-01 00:00:00

abstract：:The present study was aimed at answering the question of what patients with hepatocellular carcinomas could obtain long-term benefits from resectional therapy. The 239 patients hepatectomized from 1973 through 1986, with 33 tumor-free, 3-year survivors, were the subjects of the study. The following criteria for long-t...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamanaka N,Okamoto E

更新日期：1989-01-01 00:00:00

abstract：:A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consecutive days every 3 weeks. Five patients (19%) achieved a partial resp...

journal_title：Cancer chemotherapy and pharmacology

authors： Harstrick A,Bokemeyer C,Preusser P,Köhne-Wömpner CH,Meyer HJ,Stahl M,Knipp H,Schmoll HJ,Wilke H

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Fruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors (1, 2 and 3). This study was conducted to investigate the metabolism, excretion, and pharmacokinetics of HMPL-013 after a single oral dose to healthy Chinese men....

journal_title：Cancer chemotherapy and pharmacology

authors： Zhou S,Shao F,Xu Z,Wang L,Jin K,Xie L,Chen J,Liu Y,Zhang H,Ou N

更新日期：2017-09-01 00:00:00